| Followers | 59 |
| Posts | 7595 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Thursday, May 20, 2021 4:35:19 PM
Mr. Murphy, The sooner a BP acquires AMRN the more time they will have
to benefit from the exclusivity period thus the more money they would make.
My guess is that Mr. Mikhail is there to establish the right pricing
for Germany so that the pricing in other countries will work out and be
a solid base from which BP could negotiate pricing with additional
countries. Ideally, he is setting the price for Vazkepa in Germany
to make negotiations with other countries at prices to make it profitable,
especially for a BP that would do the detailing and distribution. The
main reason for a BP BO for Europe is that that they are in a much better
position to negotiate country by country as they have done it before
and have professional contacts. My guess is any drug launch in Europe
will be more successful if you have seasoned reps with already established
contacts detailing the drug to doctors. If BP knows how the drug will be
priced in Germany it will give them a much better handle of what sales
and profitability would be. Your post indicated that AMRN had no interest
in GIA in Europe. Maybe that would be less important if the US had not
been lost to Du. Now, Europe is critically important to AMRN as it is
the most lucrative jurisdiction with a long runway for exclusivity.
If BP takes it over they could do very well, if AMRN really does GIA
it will be another Du-saster!
to benefit from the exclusivity period thus the more money they would make.
My guess is that Mr. Mikhail is there to establish the right pricing
for Germany so that the pricing in other countries will work out and be
a solid base from which BP could negotiate pricing with additional
countries. Ideally, he is setting the price for Vazkepa in Germany
to make negotiations with other countries at prices to make it profitable,
especially for a BP that would do the detailing and distribution. The
main reason for a BP BO for Europe is that that they are in a much better
position to negotiate country by country as they have done it before
and have professional contacts. My guess is any drug launch in Europe
will be more successful if you have seasoned reps with already established
contacts detailing the drug to doctors. If BP knows how the drug will be
priced in Germany it will give them a much better handle of what sales
and profitability would be. Your post indicated that AMRN had no interest
in GIA in Europe. Maybe that would be less important if the US had not
been lost to Du. Now, Europe is critically important to AMRN as it is
the most lucrative jurisdiction with a long runway for exclusivity.
If BP takes it over they could do very well, if AMRN really does GIA
it will be another Du-saster!
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
